Symbols / TVTX
TVTX Chart
About
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 2.71B |
| Enterprise Value | 2.85B | Income | -50.26M | Sales | 490.73M |
| Book/sh | 1.26 | Cash/sh | 3.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 497 | IPO | — |
| P/E | — | Forward P/E | 7.10 | PEG | — |
| P/S | 5.52 | P/B | 23.96 | P/C | — |
| EV/EBITDA | -1371.63 | EV/Sales | 5.82 | Quick Ratio | 2.53 |
| Current Ratio | 2.74 | Debt/Eq | 286.28 | LT Debt/Eq | — |
| EPS (ttm) | -1.03 | EPS next Y | 4.26 | EPS Growth | — |
| Revenue Growth | 73.40% | Earnings | 2026-04-30 | ROA | -6.55% |
| ROE | -57.80% | ROIC | — | Gross Margin | 55.91% |
| Oper. Margin | -25.00% | Profit Margin | -5.21% | Shs Outstand | 89.47M |
| Shs Float | 91.22M | Short Float | 16.31% | Short Ratio | 4.89 |
| Short Interest | — | 52W High | 42.13 | 52W Low | 12.91 |
| Beta | 0.81 | Avg Volume | 2.12M | Volume | 138.91K |
| Target Price | $42.71 | Recom | Strong_buy | Prev Close | $30.88 |
| Price | $30.26 | Change | -2.01% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$42.71
Mean price target
2. Current target
$30.26
Latest analyst target
3. DCF / Fair value
$-7.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.26
Low
$31.00
High
$49.00
Mean
$42.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-06 | main | Piper Sandler | Neutral → Neutral | $38 |
| 2025-11-28 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-11-04 | main | Piper Sandler | Neutral → Neutral | $35 |
| 2025-10-31 | main | TD Cowen | Buy → Buy | $40 |
| 2025-09-19 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-09-12 | main | Stifel | Hold → Hold | $25 |
| 2025-09-11 | main | Wells Fargo | Overweight → Overweight | $35 |
| 2025-09-10 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-09-03 | reit | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-08-28 | main | HC Wainwright & Co. | Buy → Buy | $47 |
| 2025-08-07 | main | Scotiabank | Sector Outperform → Sector Outperform | $31 |
| 2025-08-07 | main | Wedbush | Outperform → Outperform | $32 |
| 2025-06-11 | main | Citigroup | Buy → Buy | $32 |
| 2025-05-16 | reit | Wedbush | Outperform → Outperform | $30 |
| 2025-05-02 | reit | Wedbush | Outperform → Outperform | $30 |
| 2025-05-02 | main | Stifel | Hold → Hold | $23 |
| 2025-04-23 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-04-14 | reit | Guggenheim | Buy → Buy | $47 |
| 2025-04-10 | main | Canaccord Genuity | Buy → Buy | $47 |
| 2025-04-03 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
- Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews Wed, 25 Feb 2026 04
- Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower Losses - Has The Bull Case Changed? - simplywall.st Wed, 25 Feb 2026 04
- Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha ue, 24 Feb 2026 12
- Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail ue, 24 Feb 2026 18
- A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance Mon, 23 Feb 2026 17
- Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz ue, 24 Feb 2026 12
- Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Insider Monkey ue, 24 Feb 2026 15
- Fund Update: New $33.4M $TVTX stock position opened by Fiera Capital Corp - Quiver Quantitative Wed, 11 Feb 2026 08
- Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm Sun, 22 Feb 2026 08
- Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Nasdaq hu, 19 Feb 2026 22
- TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA - Zacks Investment Research Wed, 14 Jan 2026 08
- Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance hu, 19 Feb 2026 22
- Analysts Offer Insights on Healthcare Companies: Integra Lifesciences (IART) and Travere Therapeutics (TVTX) - The Globe and Mail Sat, 21 Feb 2026 08
- Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unveiling a 40.86% Potential Upside in the Biotech Sector - DirectorsTalk Interviews ue, 10 Feb 2026 08
- Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility? - Yahoo Finance Mon, 16 Feb 2026 21
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -511.98K | -2.39M | -1.59M | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -263.33M | -314.85M | -291.84M | -184.46M |
| TotalUnusualItems | -2.44M | -11.39M | -7.58M | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -2.44M | -11.39M | -7.58M | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -320.63M | -376.33M | -331.47M | -217.29M |
| ReconciledDepreciation | 43.55M | 38.53M | 20.72M | 12.75M |
| ReconciledCostOfRevenue | 7.74M | 11.45M | 4.42M | 3.82M |
| EBITDA | -265.77M | -326.25M | -299.42M | -184.46M |
| EBIT | -309.33M | -364.78M | -320.14M | -197.20M |
| NetInterestIncome | 6.63M | 10.43M | -4.74M | -17.69M |
| InterestExpense | 11.18M | 11.33M | 11.01M | 19.68M |
| InterestIncome | 17.82M | 21.77M | 6.28M | 1.99M |
| NormalizedIncome | -318.70M | -367.33M | -325.48M | -217.29M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -321.55M | -111.40M | -278.48M | -180.09M |
| TotalExpenses | 554.56M | 521.98M | 429.27M | 331.26M |
| TotalOperatingIncomeAsReported | -323.83M | -388.14M | -319.81M | -199.43M |
| DilutedAverageShares | 78.89M | 74.27M | 63.76M | 59.83M |
| BasicAverageShares | 78.89M | 74.27M | 63.76M | 59.83M |
| DilutedEPS | -4.08 | -1.50 | -4.37 | -3.01 |
| BasicEPS | -4.08 | -1.50 | -4.37 | -3.01 |
| DilutedNIAvailtoComStockholders | -321.55M | -111.40M | -278.48M | -180.09M |
| NetIncomeCommonStockholders | -321.55M | -111.40M | -278.48M | -180.09M |
| NetIncome | -321.55M | -111.40M | -278.48M | -180.09M |
| NetIncomeIncludingNoncontrollingInterests | -321.55M | -111.40M | -278.48M | -180.09M |
| NetIncomeDiscontinuousOperations | -915.00K | 264.93M | 52.99M | 37.20M |
| NetIncomeContinuousOperations | -320.63M | -376.33M | -331.47M | -217.29M |
| TaxProvision | 120.00K | 223.00K | 313.00K | 409.00K |
| PretaxIncome | -320.51M | -376.11M | -331.15M | -216.88M |
| OtherIncomeExpense | -5.76M | -9.80M | -6.60M | 231.00K |
| OtherNonOperatingIncomeExpenses | -3.32M | 1.59M | 974.00K | 231.00K |
| SpecialIncomeCharges | -2.44M | -11.39M | -7.58M | 0.00 |
| OtherSpecialCharges | 7.58M | |||
| WriteOff | 0.00 | |||
| ImpairmentOfCapitalAssets | 0.00 | |||
| RestructuringAndMergernAcquisition | 2.44M | 11.39M | 0.00 | 0.00 |
| NetNonOperatingInterestIncomeExpense | 6.63M | 10.43M | -4.74M | -17.69M |
| InterestExpenseNonOperating | 11.18M | 11.33M | 11.01M | 19.68M |
| InterestIncomeNonOperating | 17.82M | 21.77M | 6.28M | 1.99M |
| OperatingIncome | -321.39M | -376.74M | -319.81M | -199.43M |
| OperatingExpense | 546.82M | 510.53M | 424.85M | 327.44M |
| ResearchAndDevelopment | 282.70M | 244.99M | 227.33M | 201.16M |
| SellingGeneralAndAdministration | 264.12M | 265.54M | 197.52M | 126.28M |
| GeneralAndAdministrativeExpense | 264.12M | 265.54M | 197.52M | 126.28M |
| OtherGandA | 264.12M | 265.54M | 197.52M | 126.28M |
| GrossProfit | 225.43M | 133.79M | 105.04M | 128.02M |
| CostOfRevenue | 7.74M | 11.45M | 4.42M | 3.82M |
| TotalRevenue | 233.18M | 145.24M | 109.46M | 131.84M |
| OperatingRevenue | 233.18M | 145.24M | 109.46M | 131.84M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 87.45M | 75.37M | 64.29M | 62.49M |
| ShareIssued | 87.45M | 75.37M | 64.29M | 62.49M |
| NetDebt | 320.45M | 319.09M | 313.86M | 60.83M |
| TotalDebt | 401.58M | 404.78M | 407.49M | 261.99M |
| TangibleBookValue | -44.94M | 96.32M | -54.27M | 153.71M |
| InvestedCapital | 438.06M | 578.07M | 418.40M | 528.69M |
| WorkingCapital | 215.95M | 438.87M | 344.27M | 458.74M |
| NetTangibleAssets | -44.94M | 96.32M | -54.27M | 153.71M |
| CapitalLeaseObligations | 22.60M | 27.52M | 31.94M | 35.41M |
| CommonStockEquity | 59.08M | 200.81M | 42.85M | 302.11M |
| TotalCapitalization | 369.39M | 578.07M | 418.40M | 528.69M |
| TotalEquityGrossMinorityInterest | 59.08M | 200.81M | 42.85M | 302.11M |
| StockholdersEquity | 59.08M | 200.81M | 42.85M | 302.11M |
| GainsLossesNotAffectingRetainedEarnings | -80.00K | -1.46M | -2.91M | -562.00K |
| OtherEquityAdjustments | -80.00K | -1.46M | -2.91M | -562.00K |
| RetainedEarnings | -1.45B | -1.13B | -1.01B | -765.97M |
| AdditionalPaidInCapital | 1.51B | 1.33B | 1.06B | 1.07B |
| CapitalStock | 9.00K | 7.00K | 6.00K | 6.00K |
| CommonStock | 9.00K | 7.00K | 6.00K | 6.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 535.05M | 588.10M | 629.73M | 474.52M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 334.30M | 410.19M | 487.57M | 350.43M |
| OtherNonCurrentLiabilities | 6.80M | 10.32M | 9.38M | 71.98M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 64.20M | ||
| NonCurrentDeferredLiabilities | 1.83M | 10.93M | 20.38M | |
| NonCurrentDeferredRevenue | 1.83M | 10.93M | 20.38M | |
| LongTermDebtAndCapitalLeaseObligation | 327.50M | 399.88M | 403.06M | 258.08M |
| LongTermCapitalLeaseObligation | 17.19M | 22.61M | 27.51M | 31.50M |
| LongTermDebt | 310.31M | 377.26M | 375.55M | 226.58M |
| CurrentLiabilities | 200.75M | 177.91M | 142.16M | 124.09M |
| OtherCurrentLiabilities | 14.29M | 5.24M | 12.72M | 13.59M |
| CurrentDeferredLiabilities | 2.81M | 7.10M | 11.98M | 16.27M |
| CurrentDeferredRevenue | 2.81M | 7.10M | 11.98M | 16.27M |
| CurrentDebtAndCapitalLeaseObligation | 74.08M | 4.91M | 4.43M | 3.91M |
| CurrentCapitalLeaseObligation | 5.41M | 4.91M | 4.43M | 3.91M |
| CurrentDebt | 68.68M | |||
| OtherCurrentBorrowings | 68.68M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 35.17M | 29.91M | 35.27M | 26.00M |
| PayablesAndAccruedExpenses | 74.40M | 130.76M | 77.77M | 64.33M |
| CurrentAccruedExpenses | 50.86M | 89.08M | 60.48M | 41.69M |
| Payables | 23.53M | 41.67M | 17.29M | 22.64M |
| OtherPayable | 13.49M | 7.49M | ||
| AccountsPayable | 23.53M | 41.67M | 17.29M | 15.14M |
| TotalAssets | 594.12M | 788.91M | 672.59M | 776.63M |
| TotalNonCurrentAssets | 177.47M | 172.19M | 186.19M | 193.77M |
| OtherNonCurrentAssets | 53.82M | 42.16M | 59.03M | 11.07M |
| GoodwillAndOtherIntangibleAssets | 104.02M | 104.49M | 97.12M | 148.40M |
| OtherIntangibleAssets | 103.22M | 103.69M | 96.32M | 147.50M |
| Goodwill | 800.00K | 800.00K | 800.00K | 900.00K |
| NetPPE | 19.63M | 25.54M | 30.05M | 34.30M |
| AccumulatedDepreciation | -8.76M | -7.44M | -5.20M | -3.05M |
| GrossPPE | 28.39M | 32.98M | 35.24M | 37.35M |
| Leases | 9.37M | 9.69M | 9.18M | 8.79M |
| ConstructionInProgress | 0.00 | 169.00K | 77.00K | 631.00K |
| OtherProperties | 23.20M | |||
| MachineryFurnitureEquipment | 4.72M | 5.06M | 4.99M | 4.73M |
| BuildingsAndImprovements | 14.29M | 18.06M | 21.00M | 23.20M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 416.70M | 616.77M | 486.44M | 582.83M |
| OtherCurrentAssets | 12.69M | 19.34M | 12.03M | 6.72M |
| AssetsHeldForSaleCurrent | 0.00 | 2.99M | ||
| PrepaidAssets | 6.47M | |||
| Inventory | 6.20M | 9.41M | 4.52M | 7.31M |
| FinishedGoods | 2.13M | 2.11M | ||
| WorkInProcess | 0.00 | |||
| RawMaterials | 2.40M | 5.21M | ||
| Receivables | 27.12M | 21.18M | 16.65M | 15.91M |
| TaxesReceivable | 247.00K | |||
| AccountsReceivable | 27.12M | 21.18M | 16.65M | 15.91M |
| CashCashEquivalentsAndShortTermInvestments | 370.70M | 566.85M | 450.25M | 552.88M |
| OtherShortTermInvestments | 312.17M | 508.68M | 388.56M | 387.13M |
| CashAndCashEquivalents | 58.53M | 58.18M | 61.69M | 165.75M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -338.69M | -321.61M | -214.66M | -38.94M |
| RepaymentOfDebt | 0.00 | 0.00 | -211.32M | 0.00 |
| IssuanceOfDebt | 0.00 | 0.00 | 316.25M | 0.00 |
| IssuanceOfCapitalStock | 134.74M | 191.20M | 19.55M | 224.93M |
| CapitalExpenditure | -101.21M | -41.59M | -28.37M | -24.15M |
| InterestPaidSupplementalData | 8.84M | 8.84M | 10.16M | 7.33M |
| IncomeTaxPaidSupplementalData | 16.42M | |||
| EndCashPosition | 58.53M | 58.18M | 61.69M | 165.75M |
| BeginningCashPosition | 58.18M | 61.69M | 165.75M | 84.77M |
| EffectOfExchangeRateChanges | -913.00K | 1.98M | -2.79M | 1.71M |
| ChangesInCash | 1.27M | -5.49M | -101.27M | 79.27M |
| FinancingCashFlow | 139.42M | 218.75M | 117.57M | 231.68M |
| CashFromDiscontinuedFinancingActivities | 0.00 | -1.38M | -2.48M | -6.10M |
| CashFlowFromContinuingFinancingActivities | 139.42M | 220.13M | 120.05M | 237.79M |
| NetOtherFinancingCharges | -2.10M | -2.10M | -11.98M | -2.10M |
| ProceedsFromStockOptionExercised | 6.78M | 31.04M | 7.56M | 14.95M |
| NetCommonStockIssuance | 134.74M | 191.20M | 19.55M | 224.93M |
| CommonStockIssuance | 134.74M | 191.20M | 19.55M | 224.93M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 104.93M | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 104.93M | 0.00 |
| LongTermDebtPayments | 0.00 | 0.00 | -211.32M | 0.00 |
| LongTermDebtIssuance | 0.00 | 0.00 | 316.25M | 0.00 |
| InvestingCashFlow | 99.33M | 55.78M | -32.55M | -137.62M |
| CashFromDiscontinuedInvestingActivities | 0.00 | 207.40M | 0.00 | 0.00 |
| CashFlowFromContinuingInvestingActivities | 99.33M | -151.63M | -32.55M | -137.62M |
| NetOtherInvestingChanges | -40.00K | -668.00K | -791.00K | |
| NetInvestmentPurchaseAndSale | 200.58M | -109.37M | -3.40M | -113.47M |
| SaleOfInvestment | 326.33M | 334.57M | 381.99M | 433.60M |
| PurchaseOfInvestment | -125.76M | -443.94M | -385.39M | -547.08M |
| NetIntangiblesPurchaseAndSale | -101.21M | -41.59M | -28.37M | -19.05M |
| PurchaseOfIntangibles | -101.21M | -41.59M | -28.37M | -19.05M |
| NetPPEPurchaseAndSale | -668.00K | -191.00K | -5.10M | |
| PurchaseOfPPE | -668.00K | -191.00K | -5.10M | |
| OperatingCashFlow | -237.47M | -280.02M | -186.29M | -14.79M |
| CashFromDiscontinuedOperatingActivities | -7.45M | 45.34M | 74.56M | 61.45M |
| CashFlowFromContinuingOperatingActivities | -230.02M | -325.36M | -260.85M | -76.24M |
| ChangeInWorkingCapital | -63.02M | -25.48M | 875.00K | 80.78M |
| ChangeInOtherWorkingCapital | -7.07M | -16.77M | -13.91M | 43.88M |
| ChangeInOtherCurrentLiabilities | 5.65M | -418.00K | -1.61M | 1.12M |
| ChangeInPayablesAndAccruedExpense | -48.62M | 47.08M | 24.24M | 19.14M |
| ChangeInAccruedExpense | -31.06M | 22.32M | 22.18M | 16.68M |
| ChangeInPayable | -17.56M | 24.76M | 2.06M | 2.47M |
| ChangeInAccountPayable | -17.56M | 24.76M | 2.06M | 2.47M |
| ChangeInPrepaidAssets | -3.16M | -4.66M | -5.20M | -1.44M |
| ChangeInInventory | -3.77M | -39.42M | -1.21M | 117.00K |
| ChangeInReceivables | -6.04M | -11.30M | -1.43M | 17.95M |
| ChangesInAccountReceivables | -6.00M | -11.26M | -1.06M | 853.00K |
| OtherNonCashItems | 74.87M | -1.91M | 2.97M | 15.46M |
| StockBasedCompensation | 36.91M | 44.25M | 38.14M | 29.57M |
| ProvisionandWriteOffofAssets | 2.82M | 3.04M | 1.04M | 498.00K |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -4.54M | -7.46M | -700.00K | 2.01M |
| DepreciationAmortizationDepletion | 43.55M | 38.53M | 20.72M | 12.75M |
| DepreciationAndAmortization | 43.55M | 38.53M | 20.72M | 12.75M |
| OperatingGainsLosses | 7.58M | |||
| NetIncomeFromContinuingOperations | -320.63M | -376.33M | -331.47M | -217.29M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TVTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|